Vaccinex Inc
OTCPK:VCNX
United States / Healthcare / Biotechnology
Exchange Data
Hide this widget
Price
0.61 USD
Day change
0.00 (0.00%)
52-week range
0.28 - 8.90
9:59 PM - Delayed Data
Summary of Vaccinex Inc
Hide this widget
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodeg...
Price History
Chart Gallery
Hide this widget
1 Week
1 Month
3 Months
1 Year
5 Years
10 Years
- (-)
Data Explorer
Hide this widget
Data could not be retrieved
Peer Benchmarks
Hide this widget
Quote
Value
Size
Growth
Profit
| VCNX | Peers | Sector | |
|---|---|---|---|
Market Cap | 1.633 M | 100.1 M | 64.805 M |
Price % of 52 Week High | Premium | 35.0% | 62.2% |
Dividend Yield | 0.0% | 0.0% | 0.0% |
Shareholder Yield | Premium | -32.5% | -0.7% |
1 Year Price Total Return | -91.8% | -59.4% | -11.5% |
Beta (5 Year) | 1.28 | 0.92 | 0.64 |
In the News
Hide this widget
Fair Value
Hide this widget
Average
–
Upside
–
Uncertainty
–
Spread
–
Financial Health
Health Details
Hide this widget
Financial Health for Vaccinex is determined by ranking the company on over 100 factors against companies in the Healthcare sector and operating in Developed economic markets.
12345
Financial Models for Vaccinex Inc
Model Gallery
Hide this widget
| DuPont ROE AnalysisView Updated 7 days ago |
| 10Y Historical FinancialsView Updated 7 days ago |
| 5Y Historical FinancialsView Updated 7 days ago |
| EV / EBIT MultiplesView Updated 15 hours ago |
| P/E MultiplesView Updated 15 hours ago |
| Price / Book MultiplesView Updated 15 hours ago |
| Price / Sales MultiplesView Updated 15 hours ago |
| EV / Revenue MultiplesView Updated 15 hours ago |
| CAPM WACC ModelView Updated 11 hours ago |
| 10Y DCF EBITDA ExitView Updated 15 hours ago |
| 10Y DCF Revenue ExitView Updated 15 hours ago |
| 10Y DCF Growth ExitView Updated 15 hours ago |
| 5Y DCF EBITDA ExitView Updated 15 hours ago |
| 5Y DCF Revenue ExitView Updated 15 hours ago |
| 5Y DCF Growth ExitView Updated 15 hours ago |
| Earnings Power ValueView Updated 15 hours ago |
| EV / EBITDA MultiplesView Updated 15 hours ago |
Historical Financials
Full Financials
Hide this widget
| (USD in millions) | Trailing Twelve Months | Fiscal Quarters | |||
|---|---|---|---|---|---|
| Period Ending | Dec-22 | Dec-23 | Sep-24 | Sep-23 | Sep-24 |
| Income Statement | |||||
| Revenue | 0.28 | 0.57 | 0.39 | 0.02 | 0.05 |
| Operating Income | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Net Profit | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Diluted EPS | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| EBITDA | |||||
| Balance Sheet | |||||
| Cash & ST Invest. | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Current Assets | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Total Assets | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Current Liabilities | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Total Liabilities | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Total Equity | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Total Debt | 0.48 | 0.25 | 0.06 | 0.31 | 0.06 |
| Cash Flow Statement | |||||
| Cash Flow Operations | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Cash From Investing | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Cash From Financing | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Free Cash Flow | (19) | (17) | (16) | (3.11) | (3.21) |
Analyst Notes
March 28, 2025
Hide this widget